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Magnetic resonance imaging (MRI) provides a unique tool for in vivo visualization and
tracking of stem cells in the brain. This is of particular importance when assessing
safety of experimental cell treatments in the preclinical or clinical setup. Yet, specific
imaging requires an efficient and non-perturbing cellular magnetic labeling which
precludes adverse effects of the tag, e.g., the impact of iron-oxide-nanoparticles
on the critical differentiation and integration processes of the respective stem cell
population investigated. In this study we investigated the effects of very small
superparamagnetic iron oxide particle (VSOP) labeling on viability, stemness, and
neuronal differentiation potential of primary human adult neural stem cells (haNSCs).
Cytoplasmic VSOP incorporation massively reduced the transverse relaxation time T2,
an important parameter determining MR contrast. Cells retained cytoplasmic label for
at least a month, indicating stable incorporation, a necessity for long-term imaging.
Using a clinical 3T MRI, 1 × 103 haNSCs were visualized upon injection in a gel
phantom, but detection limit was much lower (5 × 104 cells) in layer phantoms
and using an imaging protocol feasible in a clinical scenario. Transcriptional analysis
and fluorescence immunocytochemistry did not reveal a detrimental impact of VSOP
labeling on important parameters of cellular physiology with cellular viability, stemness
and neuronal differentiation potential remaining unaffected. This represents a pivotal
prerequisite with respect to clinical application of this method.
Keywords: human adult stem cells, magnetic labeling, MRI, cell tracking, CNS – disorder
INTRODUCTION
Stem cell transplantation represents one of the most promising strategies for the restoration
of lost cells or tissue including their functions, or at least for delaying the pathogenic
progress in neurodegenerative diseases (Janowski et al., 2015). The question whether adult or
embryonic stem cells are best suited for clinical applications remains open (Modo et al., 2002;
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Dietrich and Kempermann, 2006), yet adult stem cells show
reduced probability of teratoma formation, and thereby represent
a promising candidate for clinical translation (Dietrich and
Kempermann, 2006; Bellenchi et al., 2013). In humans, adult
neural stem cells are present in the subventricular zone and in
the subgranular zone of the hippocampal dentate gyrus (Zimmer
et al., 1995; Stroh et al., 2005, 2009). These cells can be isolated
from patients with intractable temporal lobe epilepsy subjected
to neurosurgical intervention (Hoehn et al., 2002). Stem cells
tracking and long term monitoring is demanded for thorough
development of safe and efficient transplantation protocols and
to further our understanding about therapeutic modes of action
in both the preclinical and clinical setting.
To date, magnetic resonance imaging (MRI) of magnetically
labeled stem cells represents the only clinically applicable
imaging method for highly sensitive, non-invasive detection
and long-term tracking of transplanted stem cells over
extended periods of time (Modo et al., 2002; Stroh et al.,
2005, 2009). Citrate-coated very small superparamagnetic
iron oxide particles (VSOP) are widely used for pre-
transplantation stem cell labeling. These particles are
incorporated via endocytosis, aggregate and ultimately get
stored in intracytoplasmic vesicles (Zimmer et al., 1995; Stroh
et al., 2005). Incorporation of VSOP can be enhanced by
lipofection to enhance the percentage of strongly labeled cells
(Hoehn et al., 2002). Superparamagnetic iron oxide particles
also seem to be biodegradable (Weissleder et al., 1989) and
can even be utilized by the cells in iron metabolism pathways
(Pouliquen et al., 1991).
However, the incorporation of iron oxide particles may lead
to distinct changes in stem cell physiology (Stroh et al., 2004;
Guzman et al., 2007; Focke et al., 2008; Neri et al., 2008).
Moreover, superparamagnetic iron oxide/poly-L-lysine-labeling
of a mouse neural stem cell line was reported to induce changes
in expression of genes responsible for iron homeostasis, despite
apoptotic pathways were not upregulated in that particular
study (Walczak et al., 2006). Further, iron oxide particles have
been shown to cause transient oxidative stress, closely linked
to the free iron during incubation (Stroh et al., 2004), and
most likely due to degradation and release of ferric ions into
the acidic endolysosomal compartments (Soenen et al., 2011).
Thus, evaluating the safety and impact of VSOP labeling on the
differentiation potential of highly sensitive human adult stem
cells is an important prerequisite for clinical translation (Gupta
et al., 2007). Finally, the intended labeling protocol needs to
be tailored to the respective stem cell population to ensure an
acceptable balance between labeling intensity/efficacy and safety
(Boltze et al., 2015).
Our study investigates describe the long term efficacy of
human adult human neural stem cell (haNSC) VSOP labeling and
its impact on viability, expansion, and neuronal differentiation
potential for the first time. We analyzed both non-differentiated
haNSCs as well as mature haNSCs-derived neurons, with murine
embryonic stem cells (mESC) serving as cellular controls.
We also assessed cell detection limit in vitro MRI with
different modalities including one being close to a potential
clinical application.
RESULTS
Safety of Cell Labeling With VSOP
To assess safety of haNSC preparation, cryopreservation, and
labeling (0.5 mM), or to detect any donor-dependent differences,
cell viability was tested in the first step. No significant donor-
dependent differences in cell viability between cells which
underwent the labeling procedure with 0.5 mM (85–89%) and
non-labeled control cells (91%, sample pooled from all patients)
could be detected 1 day after labeling (Figure 1A). All samples
could be included in onward experiments according to preset
viability criteria (>80%). Next, cell viability of haNSCs and
mESCs was compared 8 and 48 h after labeling with 0.5 and
1.5 mM VSOP, respectively (Figure 1B). Again, no significant
differences in haNSCs viability between non-labeled control cells
(95%), as well as 8 (87.5%) and 48 h (94.5%) after labeling became
apparent. Viability of mESCs decreased slightly to 89% at 8 h
and to 93.5% at 48 h after labeling. No viability differences were
observed between 0.5 and 1.5 mM VSOP concentration.
Efficacy of Magnetic Cell Labeling
Incubation of haNSCs with 0.5 mM VSOP alone (“simple”) and
additional lipofection resulted in a substantial uptake of magnetic
label (Figure 2). Prussian blue staining revealed a homogenous
ferric ion distribution in the cytoplasm, excluding the nuclei
(Figures 2a,b). Prussian blue signals remained unchanged from
day 2 to day 28 post simple incubation (Figures 2c,d), indicating
a stable vesicular incorporation of VSOP for at least 1 month.
This ratio did not differ significantly between day 2 and day 28.
No apparent increase in iron-oxide particle uptake was observed
upon visual inspection in lipofected cells (Figures 2e,f), which
was confirmed by counting labeled cells. Overall, 96–100% of
haNSCs were labeled. Labeling efficacy could not be improved
significantly at any time point by additional lipofection (+L)
(Figure 2g), so lipofection was omitted in all further experiments.
Proliferation Assays
We next conducted a proliferation assay of labeled and non-
labeled haNSCs. Over the course of 8 days, an exponential
increase in cell number could be observed, yet, notably, no
significant difference could be detected between the proliferation
curves on non-labeled and haNSCs incubated with 0.5 and
1.5 mM VSOP (Figure 2h).
Magnetic Resonance Properties
Next, the impact of 0.5 and 1.5 mM VSOP-labeling of both
stem cell populations on magnetic resonance properties was
determined after 8 and 48 h via NMR relaxometry (Figures 3a,b).
Unlabeled cells had a T2 time of 2110 ms (mESCs) and
1948 ms (haNSCs), revealing no significant difference between
both protocols. In contrast, VSOP-labeling with 0.5 mM and 8 h
incubation time led to a significant reduction of T2 time to 10%
of control values (mESCs: 218 ms, haNSCs: 227 ms, Figure 3a,
P < 0.01). 48 h after incubation, T2 time ranged at 15% of
control values (mESCs: 298 ms, haNSCs: 408 ms, Figure 3b).
Further increasing VSOP concentrations to 1.5 mM resulted in
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FIGURE 1 | Cell viability of magnetically labeled haNSCs and mESCs (n = 3 with 3 technical replicates each). (A) Trypan blue exclusion test showed no significant
differences in viability of three different patient samples (labeling with 0.5 mM). (B) Trypan blue exclusion test 8 and 48 h after labeling showed no decrease in cell
viability due to the labeling procedure.
an additional reduction of average T2 time which, however, was
not statistically significant from that after 0.5 mM incubation.
In vitro MR Imaging
To assess clinical applicability of the labeling protocol, gradient
echo MR images of gel phantoms with injected cells were
acquired (Figures 3c,g). On the T2∗-weighted images two needle
tracks on the gel surface can be delineated as hyperintense signal
changes (Figure 3c) in injection phantoms. On the left side of
the phantom 1× 103 magnetically labeled haNSCs were injected,
whereas 1 × 103 unlabeled control haNSCs where placed on the
right side. The T2∗-weighted images clearly showed hyperintense
signal changes only in the left injection track deposit of 1 × 103
labeled haNSCs (Figures 3d,e). Cell detectability was lower in
layer phantoms imaged at 3T SWI with a protocol that could be
applied on hypothetical patient. Only 5 × 104 labeled cells were
detectable with the applied imaging protocol (Figures 3f,g).
Characterization of Non-differentiated
VSOP Labeled Stem Cells
Cells were magnetically labeled and subsequently analyzed by
RT-PCR and Western Blotting (Figure 4a). Non-labeled haNSCs
and mESCs served as cellular controls. After culturing in the
appropriate expansion media, all cells except the HT22 expressed
the mRNA for the stemness markers Oct4 and Sox2, and the
neural progenitor marker nestin. haNSCs and mESCs loaded
with 0.5 mM VSOP (VSOP) or VSOP plus lipofection agent
(VSOP + L) revealed the same mRNA expression pattern. No
difference between stem cells incubated with (L) and without
lipofectin became apparent.
Analysis of haNSCs using fluorescent immunocytochemistry
showed that 99% of cells express the intermediate filament
protein nestin (Figure 4b). 65% co-expressed the nuclear
proliferation marker Ki-67 (Figures 4c,d). 99% of haNSCs,
which underwent the VSOP-labeling procedure and
subsequently had a high cytoplasmatic iron loading, expressed
nestin while 64% of cells were found positive for Ki-67
(Figures 4e–g). Substantial differences between control
cells and VSOP labeled haNSCs from all three donors
could not be observed (Figure 4h). Analysis of nestin and
Ki-67 co-expression revealed no impact of VSOP labeling
(Figure 4i). However, we found a significant effect on relative
numbers of cells co-expressing nestin and Ki-67 in the three
patients (P < 0.01).
Differentiation Potential of
VSOP-Labeled Stem Cells
Figure 4j illustrates the analysis of stem cells that were
magnetically labeled and subsequently neuronally differentiated
over 15 days. Non-labeled, but neuronally differentiated haNSCs
and mESCs served as controls. To characterize the transition
from neural progenitors to mature neurons, mRNA expression
levels of β-tubulin III, doublecortin (DCX), neural cell adhesion
molecule 1 (NCAM-1) as well as microtubule associated
phosphoprotein 2 (MAP-2) were investigated. RT-PCR analysis
indicated neural progenitors and immature neurons in control
cell populations as well as in magnetically loaded cell populations.
No differences in expression patterns were observed.
DISCUSSION
In this study, we were able to show that labeling of haNSC with
iron-oxide-particles, required for a high-resolution MR Imaging,
is both safe and efficient. Labeling efficiency using 0.5 mM VSOP
was found up to 100% and resulted in stable cell labeling for
at least 1 month. Trypan blue exclusion tests at different time
points and comparison of different patient samples demonstrated
that VSOP-labeling had no effect on overall haNSCs viability.
Using clinical 3T MRI, we visualized 1 × 103 labeled cells in an
injection phantom, modeling the in vivo situation under optimal
imaging conditions. Moreover, 3T SWI MRI of layer phantoms
with layers containing up to 5× 104 labeled cells was performed,
applying an imaging protocol taking 41:00 min. This is short
enough to be applied in a hypothetical clinical scenario, but on
the upper limit what could be performed in critically ill patients.
The protocol settings were chosen on optimal detectability in
VSOP-labeled mesenchymal stem cells (Stroh et al., 2011). The
analysis of Oct4 and Sox2 mRNA-expression in addition to the
quantitative fluorescence immunocytochemistry analysis of Ki-
67 and nestin co-expression as stem cell markers and indicators
of proliferation activity showed no impact of VSOP labeling, but
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FIGURE 2 | Cytological analysis of magnetically labeled haNSCs (n = 3 with 3
technical replicates each). (a) Unlabeled control cells and (b) intracytoplasmic
VSOP uptake by haNSCs following incubation with 0.5 mM VSOP. (c–f) Cells
were fixed with 4% phosphate-buffered saline-buffered paraformaldehyde and
intracellular iron was visualized using Prussian blue staining on day 2 as
shown in (c,e) and on day 28 as provided in (d,f) after labeling. (g) Cell
counting revealed that labeling efficacy at any time point could not be
enhanced significantly by lipofection. (h) Proliferation analysis of VSOP-labeled
haNSC (1.5 mM) revealed no statistically significant difference in the
proliferation abilities of unlabeled haNSC and haNSCs labeled with 0.5 mM
VSOP, respectively. Scale bars in (a–f) represent 10 µm. ∗p < 0.01.
significant differences in haNSC samples from different donors.
Furthermore, neuronal differentiation potential and neuronal
marker expression were not affected by the labeling procedure.
Prussian blue staining resulted in a homogenous ferric ion
distribution in the cytoplasm, but not in the nucleus. This
is in line with previous findings from our group, showing a
direct relation between VSOP incubation, intracellular iron load
as measured by atomic absorption spectroscopy, and T2 time
reduction (Stroh et al., 2005). Prussian blue staining was found
stable after 48 h and 28 days, indicating a transfer of VSOP
onto daughter cells during cytokinesis for proliferating cells. Our
data indicate no difference in labeling efficiency and stability
between incubation with VSOP and additional lipofection. One
explanation of the efficient incorporation with VSOP alone
could be the small diameter and the negative surface charge
of the citrate coating, already allowing efficient uptake without
additional lipofection. Albeit lipofection did not raise a safety
concern in our study, off-target effects and immune response
caused by transfection reagents have been described (Bauer
et al., 2006). Thus, sufficient labeling with VSOP but omitting
lipofection may represent a clear advantage for subsequent in vivo
and clinical applications.
It is known that citrate coating may interact with the
extracellular domain of integrins and triggers their activation and
subsequently intracellular signaling cascades (Miller et al., 2010).
Furthermore, VSOP can induce increased levels of transferrin
receptor-1. VSOP incubation can also result in a fast increase
and high level of reactive oxygen species (ROS), most likely
due to degradation and release of ferric ions into the acidic
endolysosomal compartments (Soenen et al., 2011). Although no
detrimental influence has been shown in the present study, the
overall impact of these potential alterations should be carefully
controlled after in vivo transplantation. While measures of T2
relaxation times provide an indication of the cellular iron uptake,
a direct measure of iron content, as conducted in previous studies
of ours using the same iron-oxide particles, yet in different cells,
would be desirable (Stroh et al., 2005, 2009). We were not able to
conduct these assays due to the scarcity of the cellular material.
Also, iron-oxide particles have shown to induce oxidative stress
(Stroh et al., 2004), potentially leading to oxidative damage to
proteins, lipids and even DNA, also at low concentrations of
the label (Novotna et al., 2012). Viability assays, as conducted
here, might not be sensitive toward these molecular changes, but
again, we were not able to conduct these assays due to the limited
availability of the cells.
Potential effects of iron oxide on the neuronal differentiation
potential of haNSC and mESC, were analyzed on the gene
transcription level. The present data indicates that VSOP-
labeled haNSCs and mESCs can be expanded without affecting
their potential for both neurogenesis, as represented by the
pluripotency markers Sox2 (Suh et al., 2007) and Oct4 (Nichols
et al., 1998), or their ability for neuronal differentiation.
Magnetic labeling had also no impact on mRNA transcription
of nestin and Ki-67 expression even after 14 days in culture.
In this study, we used iron-oxide nanoparticles, which are
presumably taken up by the cells by endocytosis (Stroh
et al., 2004). This means, that in contrast to genetically
encoded labels, the concentration of particles in the cells will
diminish over time, both due to cell proliferation, and also
due to particle degradation. This limits the time window,
in which these cells will be detectable by MRI. What is
more, we provided data on RNA level on the differentiation
potential of these labeled cells, but this does not prove
a functional stable differentiation into a given neuronal
subtype. For that, additional assays on protein level and
ultimately electrophysiological evidence need to be conducted
(Stroh et al., 2011).
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FIGURE 3 | NMR relaxometry and gradient echo MR images of gel phantoms containing haNSCs (n = 3 or more). (a,b) Efficiency of VSOP-labeling was determined
after 8 (a) and 48 h (b) using NMR relaxometry. All data were analyzed and presented as mean ± SEM. Differences were considered significant at P < 0.01.
(c) Coronal section at gel surface showing two needle tracks as hyperintense signal change. 1 × 103 VSOP labeled haNSCs were injected on the left side; on the
right side 1 × 103 unlabeled control haNSCs were injected. (d) Slice 4.5 mm ventral of (c). In the left injection track an area of signal loss can be visualized, due to
clusters of magnetically labeled haNSCs. No signal change in the right injection track was observed. (e) Slice 5 mm ventral of (c). The left injection track again shows
an area of signal loss, no signal change in the right injection track. (f,g) layer phantoms investigated in 3T SWI MRI. Only 5 × 104 labeled haNSCs were detectable
with an imaging protocol being short enough (41:00 min) to be applicable in a hypothetical clinical scenario. ∗p < 0.01.
1 × 103 VSOP-labeled haNSC were easily identified in a
gel phantom, reliably modeling the situation upon stereotactic
transplantation in vivo (Stroh et al., 2005). This detection
range is more than sufficient to monitor cell migration in
clinical scenarios where 20 to 300 × 103 or even more cells
are transplanted (Kondziolka et al., 2004; Stover et al., 2005).
Nevertheless, the detection limit is rather high compared to
other studies that repeatedly shown single cell detectability.
A direct comparison is difficult though. For instance, some
studies employed ultra-high field strengths (11.7T) and imaging
protocols optimized for that purpose (Hinds et al., 2003).
Others used long imaging times and different cell types such
MDA-MB-231BR breast cancer cells or J774 macrophages
(Heyn et al., 2006). Both cell types are much larger (up to 25 µm
diameter and up to 100 µm in length for MDA-MB-231BR) than
neural stem cells and therefore can store much higher amounts
of VSOP, while macrophages are particularly efficient in uptaking
VSOPs. We also had to apply relatively long scanning times
to visualize 1 × 103 labeled cells. Moreover, ultra long-term
in vivo imaging at 3T may necessitate higher cell concentrations
as cell loss or dilution of intracellular iron content due to in vivo
proliferation may reduce the overall signal obtained. It should be
noted though that cell detectability is different in gel phantom
and in vivo imaging, the latter commonly associated with higher
detection limits.
On the other hand, 3T SWI with a short-term protocol
optimized for cell detectability was only able to detect 5 × 104
cells in a layer phantom, modeling wide-spread cell distribution
as can be observed after systemic transplantation or migration.
Apart from the shorter imaging time and the lower number of
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FIGURE 4 | Transcriptional and immunohistochemical analysis of stemness
and neuronal differentiation (n = 6 to 10). (a) VSOP-labeling and lipofection of
non-differentiated stem cells; RT-PCR analysis of pluripotency markers
revealed no impact on stemness, and transcribed nestin. 99% of haNSCs
expressed the intermediate filament protein nestin, and 65% co-express the
nuclear proliferation marker Ki-67. No significant difference between control
cells and VSOP labeled haNSCs could be detected. (b–d) show unlabeled
control cells, and (e–g) give the VSOP labeled pendant. (h) Nestin expression
of haNSCs from three different patients was compared, showing that there is
neither a significant difference between patients nor between control cells or
labeled cells. (i) 65% of haNSCs co-express nestin and Ki-67, but significant
differences between the three patients become apparent. (j) Subsequent
neuronal differentiation (n = 6 to 10) resulted in a neuronal phenotype
transcribing β-tubulin III, doublecortin, N-CAM1, and MAP-2. Mature mouse
hippocampal cells HT22 served as a negative control for pluripotency markers
and as a positive control for mature neuronal markers. Scale bars represent
50 µm. ∗p < 0.01.
averages, the higher detection limit might have two potential
reasons. First, layer phantoms represent the cell distribution
seen after systemic (intraarteriell or intravenous) cell injection.
Systemic cell injection is believed to be more feasible for clinical
applications and is therefore used predominantly in ongoing
clinical trials (Cui et al., 2019). The density of cells is lower than in
injection phantoms that represent the situation after stereotactic
cell implantation procedures, being reserved for a targeted
approach requiring local cell deposits. Second, the imaging
protocol applied for layer phantom imaging was developed
for mesenchymal stem cells which are larger than haNSCs
and might therefore incorporate more VSOP leading to better
detectability. 7T MRI, which is being introduced into clinical
imaging, and allowing for detection of small local concentrations
of labeled cells while the feature of VSOP to further reduce
the longitudinal (T1) and transverse (T2) relaxation time may
provide much better cell detectability at high filed strengths in
future applications (Klug et al., 2010).
In summary, our study strongly suggests that in the
clinical setting, cell tracking using magnetic VSOP labeling
represents a safe method, capable of addressing three key
issues vital for effective transplantation strategies: location,
migration, and viability.
MATERIALS AND METHODS
Ethics Statement
Human adult neural stem cells were obtained from patients
with temporal lobe epilepsy submitted to epilepsy surgery.
Informed and written consent was given for additional
scientific investigations approved by the local ethics committee
of the University of Erlangen, in accordance with the
Declaration of Helsinki.
Human Adult Neural Stem Cell and
Murine Embryonic Stem Cell Cultures
Composition of expansion and differentiation media is given
in Table 1. After surgical en bloc resection, the dentate gyrus
was micro-dissected and dissociated mechanically followed by
enzymatic digestion as described previously (Hoehn et al.,
2002). Of the obtained cells, haNSC from passage 5 to 11
were cryopreserved, shipped to the primary investigation site
and used for all experiments. Cells were plated on poly-
L-ornithine (250 µg/mL)-/laminin (15 µg/mL, both Sigma-
Aldrich, Munich, Germany)-coated cell culture dishes (Sarstedt,
Nuembrecht, Germany) and grown in expansion medium at
37◦C and 5% CO2. Medium was changed every second day.
Cells were detached with accutase (PAA, Cölbe, Germany) at 80%
confluence, and split. Culturing over at least five passages selected
for proliferating cells.
Previously cryopreserved mouse embryonic stem cells
(mESCs, CRL-1934, ATCC, Manassas, United States) were
cultured in expansion medium (Table 1) at 37◦C and 5% CO2 on
mouse fibroblasts (CRL-1503, ATCC, Manassas, United States)
inactivated by mitomycin C (Sigma-Aldrich). Stem cells were
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TABLE 1 | Expansion and differentiation media.
haNSC mESC
Basic cell culture medium mESC-derived nestin+ neural progenitors
Knockout-DMEM and Ham’s F12, 5% knockout serum replacement, 2 mM L-glutamine, 1%
penicillin-streptomycin, 1% MEM non-essential amino acids, and 1% N2 supplement (all
Invitrogen, Karlsruhe, Germany)
Expansion Differentiation Expansion Differentiation Selection medium Expansion Differentiation
medium medium medium medium (from mESC) medium medium
Basic cell culture
medium
Basic cell culture
medium
Basic cell culture
medium
Basic cell culture
medium
Knockout-DMEM and
Ham’s F12
haNSC/mESC basic
cell culture medium
Expansion medium
+10 ng/mL basic
fibroblast growth
factor (bFGF,
Invitrogen)
+2% B-27
supplement
+0.1 mM
2-mercaptoethanol
Embryoid body
formation in bacterial
dishes for 6 days, final
differentiation in
gelatine-coated dishes
+1 % ITS supplement
(insulin-transferrin-
selenium,
Invitrogen)
+10% knockout serum
replacement
- N2 supplement
+10 ng/mL epidermal
growth factor (EGF,
Invitrogen)
+200 ng/mL sonic
hedgehog (SHH)
+15 ng/mL LIF +10 ng/mL bFGF - bFGF
+2.5 µg/mL bovine
pituitary extract (BPE,
Sigma-Aldrich)
+100 ng/mL
fibroblast growth
factor-8 (FGF-8)
On mouse fibroblasts
(CRL-1503, Sigma)
+20 ng/mL nerve
growth factor (NGF)
(Invitrogen)
+15 ng/mL leukemia
inhibitory factor (LIF,
Sigma-Aldrich)
+2 mM ascorbic acid +1× B-27
supplement
(Invitrogen)
+2 µg/mL heparin
separated from the fibroblast layer at 60% confluence by
detaching them with accutase, and transferred to gelatin-coated
cell culture dishes with daily medium changes. mESCs were
detached and transferred every other day. A fibroblast-free
mESCs culture was obtained after three passages.
Magnetic Cell Labeling and Viability
Assessment
Sterile VSOP (C200, Ferropharm, Teltow, Germany), consisting
of a 5nm iron oxide core coated with monomer citrate, resulting
in a hydrodynamic diameter of 11 nm and a negative charge
were used for labeling at 0.5 and 1.5 mM with or without
additional lipofection agent (lipofectin, Invitrogen) for 4 h
as described previously (Gupta et al., 2007). These molarities
were chosen based on previous findings showing that VSOP
labeling causes transient oxidative stress or even irreversible
cell damage (Stroh et al., 2004, 2009). Transient oxidative
stress is already observed at 1.5 mM, and higher incubation
molarities such as 3.0 or 6.0 mM cause more intensive stress
or even increase apoptosis and necrosis. In turn, higher VSOP
incubation molarities not necessarily shortens T2 relaxation
times or increases detectability, particularly in smaller cells
(Stroh et al., 2009).
Control specimens were incubated in Opti-MEM I for 4 h
instead. First, potential donor-specific viability differences
were assessed 20 h after labeling with 0.5 mM VSOP.
Only cells samples with >80% viability after labeling were
defined acceptable for further investigation. Next, cell
viability in relation to incubation molarities was assessed
8 and 48 h after VSOP incubation by the Trypan Blue
(Sigma-Aldrich) exclusion test on 10 randomly selected
regions per coverslip.
Labeling Efficacy Assessment and
haNSC Proliferation Experiments
Uptake of VSOP was evaluated using Prussian blue staining 48 h
and 28 days after VSOP labeling by phase contrast microscopy
of 10 regions per coverslip. The relative labeling efficacy was
displayed as a ratio of Prussian blue positive cells to all cells
identified by nuclear counterstaining.
After labeling with 0.5 µM or 1.5 µM VSOP (see above),
haNSCs were seeded on 12-well-plates covered with poly-
L-ornithine-covered (Sigma-Aldrich) at a density of 7,500
cells/cm2 (28,500 cells/well) on expansion medium. Unlabeled
haNSCs served as controls. Proliferation of haNSCs was
monitored over 8 days, and cell culture medium was exchanged
every second day. Cell numbers were assessed on days 1,
2, 4, and 8 in three wells for each VSOP concentration
and on each day. Experiments were performed with using
a total of six haNSC lines derived from three different
patients (n = 3).
NMR Relaxometry
Further, nuclear magnetic resonance (NMR) relaxometry was
performed to determine the T2 time (transverse relaxation time).
9 × 105 cells were suspended in 3 mL PBS and measured in
a NMR-Relaxometer Minispec 0.47T/20MHz (Bruker, Ettlingen,
Germany). Data analysis was performed using the ORIGIN
Pro 8G software (OriginLab Corporation, Northampton, MA,
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United States). All samples have been analyzed in three
independent experiments.
Clinical MR Imaging at 3 Tesla
Detectability of VSOP labeled haNSCs was assessed by in vitro
MRI. Two different types of agarose gel phantoms, cell injection
and cell layer phantoms, were used. For injection phantoms,
1 × 103 magnetically labeled haNSCs (1.5 µM VSOP) were
injected into air bubble-free gel phantoms as described previously
(Soenen et al., 2011). Briefly, 1 × 103 magnetically labeled
haNSCs were injected on one side of the phantom, and 1 × 103
non-labeled haNSCs on the other.
Injection phantom MRI was performed on a clinical 3 Tesla
scanner (Achieva 3T, Philips Medical Systems, Best, Netherlands)
under conditions optimized for cell imaging. A 3T solenoid rat
coil (RX SN 1116, Philips) with a coil diameter of 55 mm was
used. 2D gradient echo sequences were applied, with TE/TR
13.8/50 ms, a flip angle of the excitation pulse of 15◦, yielding
images that were T2∗ (effective transverse relaxation time)
weighted. Both a coronal as well as a sagittal data set was acquired
covering the entire gel phantom. The slice thickness was 0.3 mm,
the interslice distance 0.15 mm, with a 20 mm field of view, and
a 288 × 288 matrix, resulting in an inplane resolution of 69 µm
and a voxel size of 69× 69× 300 µm3.
Layer gel phantoms were produced as described elsewhere
(Lobsien et al., 2013). Two phantoms were produced, each
containing four layers in which unlabeled or VSOP-labeled
haNSCs (1.5 µM) were embedded. Layer phantom 1 contained
layers with 5 × 10, 1 × 102, 5 × 102, and 1 × 103 VSOP-labeled
haNSCs, respectively. Layer phantom 2 contained layers with
5 × 103, 1 × 104, and 5 × 104 VSOP-labeled haNSCs, as well
as a layer containing 5× 104 unlabeled haNSCs.
Layer phantom MRI was performed on a clinical 3
Tesla Scanner (Magnetom Trio, Siemens, Erlangen, Germany)
equipped with a standard 8ch knee coil. The imaging protocol
was not particularly optimized for cellular imaging but rather
to reflect a clinical situation. 3D Susepctibility-weighted images
(SWI) were obtained with TE/TR 20/60 ms at a flip-angle FA
of 15◦. A voxel size of 560 µm3 × 490 µm3 × 250 µm3 was
achieved. Acquisition time TA was 41:00 min. SWI sequences
were processed by vendor-specific software of the MRI scanner
(Syngo B15, Siemens, Erlangen, Germany) and analyzed without
further post-processing.
RT-PCR Analysis
Cells were harvested before and after magnetic labeling, and
neuronal differentiation (see below), respectively. RNA species
>200 nt were extracted using Mini RNeasy kit. cDNA synthesis
with integrated removal of genomic DNA contamination was
performed on 1 µg RNA using QuantiTect Reverse Transkription
kit (both Qiagen, Hilden, Germany). PCR was performed on 2 µl
of cDNA using Taq-DNA-Polymerase all inclusive kit (Peqlab,
Erlangen, Germany). Table 2 shows the primer sequences used
in this experiment. All samples were analyzed in at least three
independent experiments. Mature mouse hippocampal cells
HT22 were used as a negative control for pluripotency and neural
progenitor markers.
TABLE 2 | List of primers.
Gene Primer forward Primer reverse
Oct4 5′- CTCCTGAAGCAGA
AGAGGATCAC-3′
5′-CTTCTGGCGCCGG
TTACAGAACCA-3′
Sox2 5′-TGCAGTACAACT
CCATGACCA-3′
5′-GTGCTGGGACATGT
GAAGTCG-3′
nestin 5′-CAGCGTTGGAACAG
AGGTTG-3′
5′-GCTGGCACAGG
TGTCTCAAG-3′
β3-tubulin 5′-GCAAGGCCTTCC
TGCACT-3′
5′-GCGTCCTGGTACT
GCTGGTA-3′
DCX 5′-GACAGCCCACTCT
TTTGAGC-3′
5′-GCGTAGAGATGGGA
GACTGC-3′
NCAM1 5′-TATCCCAGTGCCA
CGATCTC-3′
5′-TGGCTTCCTTGGC
ATCATAC-3′
MAP-2 5′-GGTGGCAAGGTGC
AGATAAT-3′
5′-CTTTGGCATTCTCC
CTGAAG-3′(mus musculus)
MAP-2 5′-GTGGGGGTTGTC
ACAGAGG-3′
5′-GCTCTCCCAGCG
GCAAGG-3′(homo sapiens)
GAPDH 5′-CAACGAATTTGGC
TACAGCA-3′
5′-AGGGGTCTACATG
GCAACTG-3′
Fluorescence Immunocytochemistry and
Characterization
For characterization of cultured haNSCs and for determining
effects of magnetic labeling on stemness, cells were fixed
in PBS-buffered paraformaldehyde (4%). Processing,
immunocytochemistry and quantitative evaluation were
performed as described elsewhere (Heyn et al., 2006).
Mouse-anti-Ki67 (Dako, 1:100, proliferation marker), and rabbit-
anti-nestin (Millipore, 1:200, neural progenitor cell marker) were
used as primary antibodies, and Alexa Fluor 555 or 488 (both
Invitrogen, 1:100) served as secondary antibodies. Nuclei were
labeled by 4′,6-Diamidino-2-phenylindole dihydrochloride
(DAPI, Sigma-Aldrich, 1.1000). For analysis, 10 randomly
selected regions per coverslip were counted. Percentage
was determined as the number of nestin+, Ki-67+, or Ki-
67+/nestin+ cells compared to total cells identified by nuclear
DAPI counterstaining.
Neuronal Differentiation of haNSCs and
mESC
The possible interference of VSOP-labeling or lipofectin
on neuronal differentiation was also assessed. haNSC were
differentiated for 15 days in haNSC differentiation medium
(Table 1), which was changed every second day. Six independent
experiments were conducted, containing at least three technical
replicates each.
mESCs-differentiation was performed as described elsewhere
(Bibel et al., 2004) with some modifications. For embryoid
body formation expanded mESCs were transferred into bacterial
dishes and LIF was removed. After 6 days cells had aggregated
and formed embryoid bodies, which were carefully transferred
to gelatine-coated dishes. During the following 2–3 days, the
heterogeneous bodies adhered and migrating cells started to form
a monolayer. Neural progenitor cells were selected for 3 days
and then expanded in neural progenitor expansion medium
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(Table 1) for 10 days. RT-PCR analysis and Prussian blue
staining were performed as described above. Ten independent
experiments were conducted.
Statistical Analysis
Statistical analysis was conducted using SPSS (Chicago,
IL, United States) software. First, data sets from all
conditions were tested for normal distribution using the
parameter free one-sample Kolmogorov-Smirnov test. In
cases where normal distribution of data was confirmed,
the parametric two-tailed Student’s t-test was employed to
compare means. P-values <0.01 were considered statistically
significant. All data are presented as mean ± standard error
of the mean (SEM).
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